Cargando…
Increased Percentage of CD8(+)CD28(−) Regulatory T Cells With Fingolimod Therapy in Multiple Sclerosis
BACKGROUND AND OBJECTIVES: Fingolimod, an oral therapy for MS, decreases expression of membrane S1P1 receptors on CD4(+) memory cells, causing their retention and deactivation in lymph nodes. We determined fingolimod effects on the number and proportion of potentially CNS-damaging CD8(+)CD28(+) cyto...
Autores principales: | Houston, Timothy W., Howlett-Prieto, Quentin, Regenauer, Colin, Testai, Fernando D., Yao, Faith, Feng, Xuan, Reder, Anthony T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9764330/ https://www.ncbi.nlm.nih.gov/pubmed/36535763 http://dx.doi.org/10.1212/NXI.0000000000200075 |
Ejemplares similares
-
Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: Gene expression and protein profiles
por: Fong, Chloe C., et al.
Publicado: (2023) -
Corrigendum: Adaptive and innate immune responses in multiple sclerosis with anti-CD20 therapy: gene expression and protein profiles
por: Fong, Chloe C., et al.
Publicado: (2023) -
Fingolimod Increases CD39-Expressing Regulatory T Cells in Multiple Sclerosis Patients
por: Muls, Nathalie, et al.
Publicado: (2014) -
CD28(−) and CD28(low)CD8(+) Regulatory T Cells: Of Mice and Men
por: Vuddamalay, Yirajen, et al.
Publicado: (2017) -
Numerical status of CD4(+)CD25(+)FoxP3(+) and CD8(+)CD28(-) regulatory T cells in multiple sclerosis
por: Kouchaki, Ebrahim, et al.
Publicado: (2014)